Zyvox I.v. Injection

— THERAPEUTIC CATEGORIES —
  • Bacterial infections

Zyvox I.v. Injection Generic Name & Formulations

General Description

Linezolid 2mg/mL; soln for IV infusion; sodium content 0.38mg/mL.

Pharmacological Class

Oxazolidinone.

How Supplied

Tabs—20, 30; Susp—150mL; Infusion bags (100mL, 300mL)—10

Manufacturer

Generic Availability

YES

Zyvox I.v. Injection Indications

Indications

Susceptible vancomycin-resistant E. faecium (VREF) infections, nosocomial and community-acquired pneumonia, complicated skin and skin structure infections (including diabetic foot infections) without osteomyelitis, uncomplicated skin and skin structure infections.

Limitations of Use

Not for treating Gram (–) infections. Safety and efficacy of Zyvox given for longer than 28 days have not been evaluated.

Zyvox I.v. Injection Dosage and Administration

Adult

Infuse inj over 30–120 mins; switch to oral form when appropriate. VREF: 600mg every 12hrs for 14–28 days. Pneumonia, complicated skin and skin structure: 600mg every 12hrs for 10–14 days. Uncomplicated skin and skin structure (oral forms only): 12–17yrs: 600mg every 12hrs; >17yrs: 400mg every 12hrs; both for 10–14 days. MRSA: 600mg every 12hrs.

Children

Infuse inj over 30–120 mins; switch to oral form when appropriate. Neonates <7 days: see full labeling. 0–11yrs: VREF: 10mg/kg every 8hrs for 14–28 days; pneumonia, complicated skin and skin structure: 10mg/kg every 8hrs for 10–14 days. Uncomplicated skin and skin structure (oral forms only): <5yrs: 10mg/kg every 8hrs; 5–11yrs: 10mg/kg every 12hrs; both for 10–14 days.

Zyvox I.v. Injection Contraindications

Contraindications

During or within 2 weeks of MAOIs (eg, phenelzine, isocarboxazid).

Zyvox I.v. Injection Boxed Warnings

Not Applicable

Zyvox I.v. Injection Warnings/Precautions

Warnings/Precautions

Not for treating catheter-related bloodstream infections or catheter-site infections. Uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome: not recommended. History of seizures. Monitor CBC's weekly (esp. if otherwise at risk). Consider discontinuing if myelosuppression occurs or worsens. Therapy >28 days. Peripheral and optic neuropathy. Monitor visual function if treatment ≥3 months and if new visual symptoms occur. Diabetes; monitor for hypoglycemia, if occurs, reduce dose or discontinue. Hyponatremia and/or SIADH; monitor serum sodium levels (esp. in elderly, those on diuretics, others at risk of). Phenylketonuria (oral susp form). Pregnancy. Nursing mothers: monitor infants.

Zyvox I.v. Injection Pharmacokinetics

See Literature

Zyvox I.v. Injection Interactions

Interactions

See Contraindications. Concomitant sympathomimetics (eg, pseudoephedrine), vasopressive agents (eg, epinephrine, norepinephrine), dopaminergics (eg, dopamine, dobutamine): not recommended. Risk of serotonin syndrome with concomitant SSRIs, trycyclic antidepressants, bupropion, buspirone, triptans, or opioids (eg, meperidine). Avoid large amounts of dietary tyramine (keep <100mg/meal). May be antagonized by carbamazepine, phenytoin, phenobarbital. Caution with myelosuppressants.

Zyvox I.v. Injection Adverse Reactions

Adverse Reactions

Diarrhea, vomiting, nausea, anemia, headache, rash, dizziness, pruritus, tongue discoloration, taste alteration; myelosuppression (eg, anemia, thrombocytopenia), lactic acidosis, C. difficile-associated diarrhea, hypoglycemia, blurred vision, convulsions.

Zyvox I.v. Injection Clinical Trials

See Literature

Zyvox I.v. Injection Note

Not Applicable

Zyvox I.v. Injection Patient Counseling

See Literature